To prove the assumption, we established sorafenib-resistant HCC cell lines and found that the CSF3R-AS/CSF3R/JAK2/STAT3 positive feedback loop was indeed activated in the resistant cells, and blocking this loop increased the sensitivity of HCC to sorafenib, which is expected to provide a new therapeutic target for HCC. Here, CSF3R is linked to hepatocellular carcinoma.